MDXG MiMedx Group Inc.

MiMedx Files Definitive Proxy Materials

MiMedx Files Definitive Proxy Materials

MARIETTA, Ga., Aug. 03, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (“SEC”) in connection with its upcoming 2019 annual meeting of shareholders (“Annual Meeting”). The meeting is scheduled to be held on August 31, 2020 at 10:00 a.m. Eastern Time at . Shareholders as of the record date, 5:00 p.m. Eastern Time on July 14, 2020, are entitled to notice of, and to vote at, the Annual Meeting.

In light of public health concerns regarding the coronavirus (COVID-19) outbreak, the Annual Meeting will be conducted in a virtual format only to assist in protecting the health and well-being of our shareholders, directors and employees and to provide access to our shareholders regardless of geographic location.

The Company is mailing the definitive proxy statement (the “Proxy Statement”) and accompanying proxy card for the 2019 annual meeting of shareholders to its shareholders. A free copy of the Proxy Statement and other relevant documents that the Company files with the SEC may be obtained through the SEC’s website at or at the Company’s website at .

Contact:

Hilary Dixon

Investor Relations & Corporate Communications

770.651.9066

EN
03/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE

MIMEDX Announces Publication in the Journal of Inflammation Focused on...

MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro Study investigates the influence of MIMEDX DHACM and LHACM products on inflammatory response, which supports the healing cascade and tissue repair MARIETTA, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the latest addition to its industry-leading body of scientific and clinical evidence supporting the use of its dehydrated human amnion chorion membrane (DHACM...

 PRESS RELEASE

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”) Publication Adds to Large Compendium of Evidence for MIMEDX’s Leading Product Portfolio Trial Enrollment Ongoing MARIETTA, Ga., Nov. 13, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of interim results from its CAMPAIGN trial, a randomized controlled trial (“RCT”) designed to...

 PRESS RELEASE

MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 16th Annual Alpha Select Conference | New York, NYTuesday, November 18, 20251:1 sessions Canaccord MedTech, Diagnostics and Digital Health & Services Forum | New York, NYThursday, November 20, 20251:1 sessions Investors interested in meeting with senior management at these events may contact their resp...

 PRESS RELEASE

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule Company is Well Positioned to Continue to Compete and Grow MARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the CY 2026 Physician Fee Schedule (“PFS”) final rule, which was published on Friday. “Over the last several years, we have actively engaged with numerous stakeholders to advocate for much-needed reform of the Medicare reimbursement system for skin substitutes. CMS i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch